AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-21 and is reviewed periodically as new material appears.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
644 1787 L'intégration de quelques équations aux différences Partielles (Legendre transform) In Memoires présentés par divers Savants à la l'Académie des Sciences de l'Institut de France 1806 Nouvelle formula pour réduire en distances vraies les distances apparentes de la Lune au Soleil ou à une étoile (30–54) 1807 Analyse des triangles tracés sur la surface d'un sphéroide (130–161) Tome 10 Recherches sur diverses sortes d'intégrales défines (416–509) 1819 Méthode des moindres carrés pour trouver le milieu le plus probable entre les résultats de différentes observations (149–154), Mémoire sur l'attraction des ellipsoïdes homogènes (155–183) 1823 Recherches sur quelques objets d'Analyse indéterminée et particulièrement sur le théorème de Fermat (1–60) 1828 Mémoire sur la détermination des fonctions Y et Z que satisfont à l'équation 4(X^n-1) = (X-1)(Y^2+-nZ^2), n étant un nombre premier 4i-+1 (81–100) 1833 Réflexions sur différentes manières de démontrer la théorie des parallèles ou le théorème sur la somme des trois angles du triangle, avec 1 planche (367–412)
== Research == Ala-Kokko's research focuses on collagen in cartilage, and connective tissue disorders. She has, with her research group, succeeded in identifying the errors in cartilage collagen that lead to the development of osteoarthritis and diseases of the vertebrae, amongst others. Her results have assisted in the diagnosis and care of patients, as well as improvements to the way in which these diseases are treated. She has published about 160 articles based on her research, and she has been awarded five patents.
== Toxicity == When applying 5 pg/mouse via intracerebroventricular injection U7-CNTX-Pn1a was found to cause paralysis in the posterior limbs of the mice. Movement and aggression were observed to decrease within 24 h.
(1887), banker, prominent figure in Thoroughbred horse racing Richard Stevens (1890), attorney and real estate developer in Hoboken, New Jersey, grandson of inventor John Stevens and son of Stevens Institute of Technology founder Edwin Augustus Stevens Cortlandt F. Bishop (1891), aviator and book collector, grandson of philanthropist Benjamin Hazard Field Howard Gould* (1894), financier, son of railroad tycoon Jay Gould Joseph Peter Grace Sr. (1894), businessman, polo player, heir to W. R. Grace and Company; founder of Pan American-Grace Airways and Grace National Bank Samuel Bloomingdale (1895), businessman, heir to the Bloomingdale's department store fortune Dexter M. Ferry Jr. (1898), director of D.M. Ferry & Co.; member of the Michigan House of Representatives Charles A. Dana (1902), philanthropist who founded the Dana Foundation and Dana Holding Corporation John Knowles Fitch (1902), founder of Fitch Ratings, one of the Big Three rating agencies Marcellus Hartley Dodge Sr. (1903), chairman of the Remington Arms Company, husband of Geraldine Rockefeller Dodge George Earle Warren (1903), vice president of Chase Manhattan Bank Pendleton Dudley (1906), public relations executive, founder of Dudley-Anderson-Yutzy William Gage Brady Jr.
Sources: en.wikipedia.org
Freezing: Using a clear polyester bag, excess air is pushed out and heat sealed with the specimen inside or the specimen can be placed inside polythene bags and sealed with parcel tape. Then it is placed into a normal domestic freezer for at least 14 days at a temperature of −18 °C (0 °F), or for 72 hours if freezing at −30 °C (−22 °F). Anoxia: Small anoxic environments starve the pests of oxygen and are created using sealed barrier films and placing oxygen scavengers and RH buffers inside before sealing. An integrated pest management program is cost-effective over time and the best preventive measure against pests.
In November 1990, the German–Polish Border Treaty, with unified Germany, was signed. In November 1990, Lech Wałęsa was elected president for a five-year term; in December, he became the first popularly elected president of Poland. Poland's first free parliamentary election was held in October 1991. 18 parties entered the new Sejm, but the largest representation received only 12% of the total vote.
=== Culinary concerns === Jalapeños are a low-acid food with a pH of 4.8–6.0 depending on maturity and individual pepper. If canned or pickled jalapeños appear gassy, mushy, moldy, or have a disagreeable odor, then to avoid botulism, special precautions are needed to avoid illness and spread of the bacteria. Canning or packaging in calcium chloride increases the firmness of the peppers and the calcium content, whether or not the peppers are pickled as well as canned. In 2008, fresh jalapeños from Mexico were tested positive for Salmonella leading the FDA to believe that the peppers were responsible for much of the 2008 United States salmonellosis outbreak. This large outbreak of Salmonella led to increased research into the detection of pathogens on jalapeños, the frequency and behavior of foodborne illness related to jalapeños, and ways to prevent foodborne illnesses from fresh jalapeños. Contaminated irrigation water and processing water are the two most common methods by which jalapeños become contaminated, as was the case in the 2008 outbreak. Jalapeños have similar microbial properties to tomatoes. The outer layer of their skin provides a safe environment for pathogens to survive, and if damaged or chopped provides a growth medium for these pathogens. Washing fresh jalapeños is important to reduce pathogen counts both at the farm and consumer level, but without cold storage it is insufficient to prevent pathogen spread.
Sources: en.wikipedia.org
The Research Quality Association (RQA) is a not for profit membership association. Formerly known a Quality Assurance Group UK (QAG UK) and the British Association of Research Quality Assurance (BARQA), the association changed its name to RQA in December 2012 in order to be able to act in a more global role.
Benzyl (Bn) — Removed by hydrogenolysis. Bn group is widely used in sugar and nucleoside chemistry. Trityl (triphenylmethyl, Tr) — Removed by acid and hydrogenolysis p-Methoxybenzyl (PMB) — Removed by acid, hydrogenolysis, or oxidation – commonly with DDQ. p,m‑Dimethoxybenzyl — Removed via oxidation with DDQ or ceric ammonium chloride Acetals:
T-tubules are microscopic tubes that run from the cell surface to deep within the cell. They are continuous with the cell membrane, are composed of the same phospholipid bilayer, and are open at the cell surface to the extracellular fluid that surrounds the cell. T-tubules in cardiac muscle are bigger and wider than those in skeletal muscle, but fewer in number. In the centre of the cell they join, running into and along the cell as a transverse-axial network. Inside the cell they lie close to the cell's internal calcium store, the sarcoplasmic reticulum. Here, a single tubule pairs with part of the sarcoplasmic reticulum, called a terminal cisterna, in a combination known as a diad. The functions of T-tubules include rapidly transmitting electrical impulses known as action potentials from the cell surface to the cell's core, and helping to regulate the concentration of calcium within the cell in a process known as excitation-contraction coupling. They are also involved in mechano-electric feedback, as evident from cell contraction induced T-tubular content exchange (advection-assisted diffusion), which was confirmed by confocal and 3D electron tomography observations.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.